TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14518728

Group type: EXPERIMENTAL
Intervention: Computer-aided diagnostic system using neural network classifiers for classification of hepatic lesions.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feature extraction module calculating average gray level and 48 texture characteristics.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three sequentially placed feed-forward neural networks (NNs) for classification.
Number of subjects: 0
Study: 10648311

Group type: EXPERIMENTAL
Intervention: Sevoflurane (S)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Halothane (H)
Number of subjects: 51
Study: 8712329

Group type: COMPARATOR
Intervention: Buprenorphine 2.5 micrograms.kg‐1
Number of subjects: 75

Group type: COMPARATOR
Intervention: Buprenorphine 5 micrograms.kg‐1
Number of subjects: 75

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 75
Study: 1947865

Group type: EXPERIMENTAL
Intervention: Community Care (CC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Non-schizophrenic patients
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Schizophrenic patients
Number of subjects: 16
Study: 6387563

Group type: EXPERIMENTAL
Intervention: Healon
Number of subjects: 40

Group type: COMPARATOR
Intervention: Air/BSS (Control)
Number of subjects: 40
Study: 29300100

Group type: EXPERIMENTAL
Intervention: UC + CALM ARC (7-session, group-based, computer-assisted but therapist-directed treatment)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 97
Study: 28416391

Group type: EXPERIMENTAL
Intervention: Out-of-plane ultrasound guidance (Group I, n = 43)
Number of subjects: 86

Group type: COMPARATOR
Intervention: In-plane ultrasound guidance (Group II, n = 43)
Number of subjects: 86
Study: 25917860

Group type: EXPERIMENTAL
Intervention: Heated lidocaine/tetracaine patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subacromial corticosteroid injection
Number of subjects: 0
Study: 24169242

Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 221

Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 221
Study: 21915866

Group type: EXPERIMENTAL
Intervention: PEG‐IFN alfa‐2b for 52 weeks
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo for 48 weeks
Number of subjects: 303
Study: 18249219

Group type: EXPERIMENTAL
Intervention: Changes in moderate-to-vigorous physical activity (PA)
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Changes in total and moderate-to-vigorous physical activity (PA)
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Changes in total physical activity (PA)
Number of subjects: 487
Study: 16801300

Group type: EXPERIMENTAL
Intervention: Nicotinized cigarette
Number of subjects: 11

Group type: COMPARATOR
Intervention: Denicotinized cigarette
Number of subjects: 11
Study: 12765960

Group type: EXPERIMENTAL
Intervention: Normal Glucose Tolerance (NGT)
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: Impaired Fasting Glucose (IFG) - Impaired Glucose Tolerance (IGT)
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: Abnormal FPG
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: Impaired FPG or 2hPG
Number of subjects: 815
Study: 11128360

Group type: EXPERIMENTAL
Intervention: 1.25 mg ramipril
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 5 mg ramipril
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Combined ramipril treatment
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Ramipril (both doses)
Number of subjects: 140
Study: 8775534

Group type: EXPERIMENTAL
Intervention: Enalapril therapy
Number of subjects: 0
Study: 1427244

Group type: EXPERIMENTAL
Intervention: Self-management education program
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 324
Study: 6374533

Group type: EXPERIMENTAL
Intervention: Single 150 mg intramuscular dose of netilmicin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Five-day course of oral co-trimoxazole
Number of subjects: 42
Study: 30707598

Group type: EXPERIMENTAL
Intervention: Nutrition-related practices reported by providers
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Hispanic providers' feeding practices
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Hispanic providers' unhealthy food practices
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Hispanic providers' screen usage during meals
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Hispanic providers' nutrition training
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: NAP SACC practices met by providers
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Ethnic differences in meeting NAP SACC guidelines
Number of subjects: 166
Study: 29634843

Group type: EXPERIMENTAL
Intervention: Diffractive trifocal IOL (AT LISA tri 839MP; Carl Zeiss Meditec)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Diffractive bifocal IOL (AT LISA 809M; Carl Zeiss Meditec)
Number of subjects: 55
Study: 27002181

Group type: EXPERIMENTAL
Intervention: NS3623 (dual K(+) current activator)
Number of subjects: 0
Study: 24318410

Group type: EXPERIMENTAL
Intervention: Continuous absorbable intradermal sutures
Number of subjects: 193

Group type: COMPARATOR
Intervention: Interrupted nonabsorbable sutures
Number of subjects: 193
Study: 22908698

Group type: EXPERIMENTAL
Intervention: Fortified flour with seven vitamins and minerals
Number of subjects: 300

Group type: COMPARATOR
Intervention: Unfortified flour
Number of subjects: 300
Study: 20207695

Group type: EXPERIMENTAL
Intervention: Nebulization with hypertonic saline 30 min before gastric lavage (n = 36)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Gastric lavage without prior nebulization (n = 68)
Number of subjects: 104
Study: 17439600

Group type: EXPERIMENTAL
Intervention: Cornstarch-thickened formula (group A)
Number of subjects: 81

Group type: COMPARATOR
Intervention: 25% strengthened regular formula (group B)
Number of subjects: 81
Study: 16355647

Group type: EXPERIMENTAL
Intervention: Supervised tooth-brushing with 1.23% APF gel (1 minute once a week)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Supervised tooth-brushing with placebo
Number of subjects: 258

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 258
Study: 12386505

Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheter (PAC) led therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 9474450

Group type: EXPERIMENTAL
Intervention: Crazy lens
Number of subjects: 9

Group type: COMPARATOR
Intervention: Clear lens
Number of subjects: 9
Study: 7656962

Group type: EXPERIMENTAL
Intervention: Prototype small-volume steel holding chamber
Number of subjects: 164

Group type: COMPARATOR
Intervention: Large-volume, single-valved plastic Nebuhaler
Number of subjects: 164
Study: 2666640

Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT, Retrovir)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 201440

Group type: EXPERIMENTAL
Intervention: 1 mg fluoride as NaF in a watery solution
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 1 mg fluoride in tablet form (D‐Fluoretten 1000)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 6
Study: 31146772

Group type: EXPERIMENTAL
Intervention: Acupuncture (n = 42)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sham control (n = 42)
Number of subjects: 84
Study: 28032641

Group type: EXPERIMENTAL
Intervention: Early tumor shrinkage (ETS) observed in first-line treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minor early tumor shrinkage (mETS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minor progression (mPD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progression (PD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early tumor shrinkage (ETS) in second-line therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minor early tumor shrinkage (mETS) in second-line therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minor progression (mPD) in second-line therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progression (PD) in second-line therapy
Number of subjects: 0
Study: 26444022

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 36
Study: 23660094

Group type: EXPERIMENTAL
Intervention: Inosine within 6 hours (600 mg twice a day for 10-14 days)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Inosine after 6 hours (600 mg twice a day for 10-14 days)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Conventional therapy group (routine treatments)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: All groups (including inosine and control)
Number of subjects: 85
Study: 21500884

Group type: EXPERIMENTAL
Intervention: Dissonance-based prevention program
Number of subjects: 306

Group type: COMPARATOR
Intervention: Educational brochure control condition
Number of subjects: 306
Study: 19515754

Group type: EXPERIMENTAL
Intervention: Community Parent Education Program (COPE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical intervention group
Number of subjects: 0
Study: 17350370

Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg twice daily
Number of subjects: 64

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 64
Study: 15611205

Group type: EXPERIMENTAL
Intervention: Self-management program for chronic illness
Number of subjects: 0
Study: 11779601

Group type: EXPERIMENTAL
Intervention: Homozygous beta-thalassemia patients
Number of subjects: 130

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 130
Study: 9667227

Group type: EXPERIMENTAL
Intervention: Melatonin (MEL) 12 mg orally
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Pyridostigmine 60 mg orally
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Combination of MEL and pyridostigmine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Naloxone (1.2 mg bolus followed by i.v. infusion of 1.6 mg/h for 3 hours)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 8134442

Group type: EXPERIMENTAL
Intervention: Oxygen therapy at 2.5 atmospheres for 90 minutes, 5 days per week for 30 treatments
Number of subjects: 16

Group type: COMPARATOR
Intervention: Air therapy at 2.5 atmospheres for 90 minutes, 5 days per week for 30 treatments
Number of subjects: 16
Study: 2510265

Group type: EXPERIMENTAL
Intervention: Rioprostil, 300 micrograms b.d.
Number of subjects: 194

Group type: COMPARATOR
Intervention: Ranitidine, 150 mg b.d.
Number of subjects: 194
Study: 4560728

Group type: EXPERIMENTAL
Intervention: Benorylate
Number of subjects: 15

Group type: COMPARATOR
Intervention: Soluble aspirin
Number of subjects: 15
Study: 30239456

Group type: EXPERIMENTAL
Intervention: Exponential tapering (n = 79)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Linear tapering (n = 79)
Number of subjects: 158
Study: 30796456

Group type: EXPERIMENTAL
Intervention: ICD implantation
Number of subjects: 1116

Group type: COMPARATOR
Intervention: Control (usual clinical care)
Number of subjects: 1116
Study: 28905498

Group type: EXPERIMENTAL
Intervention: Bimagrumab 30 mg/kg i.v.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 26369371

Group type: EXPERIMENTAL
Intervention: Prenatal surgery
Number of subjects: 183

Group type: COMPARATOR
Intervention: Postnatal repair
Number of subjects: 183
Study: 23506744

Group type: EXPERIMENTAL
Intervention: Dignity therapy (DT) + standard palliative care (SPC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard palliative care (SPC) alone
Number of subjects: 60
Study: 21725053

Group type: EXPERIMENTAL
Intervention: WRAPID pharmacogenetics-guided initiation protocol
Number of subjects: 167
Study: 19837300

Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of recombinant human erythropoietin (rHuEPO) at 150 IU/kg, 4 doses at 48-hour intervals
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group received 0.5 mL/kg isotonic solution
Number of subjects: 16
Study: 16376081

Group type: EXPERIMENTAL
Intervention: 27 gauge needle
Number of subjects: 90

Group type: COMPARATOR
Intervention: 23 gauge needle
Number of subjects: 90
Study: 12753365

Group type: EXPERIMENTAL
Intervention: rPrtC of Porphyromonas gingivalis
Number of subjects: 34
Study: 12638099

Group type: EXPERIMENTAL
Intervention: Heatwrap therapy
Number of subjects: 219

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 219
Study: 9607135

Group type: EXPERIMENTAL
Intervention: Intravenous procainamide (1 g over 30 minutes, followed by an infusion of 2 mg/min over 1 hour)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 8553118

Group type: EXPERIMENTAL
Intervention: Flexion exercise and posture
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Extension exercise and posture
Number of subjects: 149

Group type: COMPARATOR
Intervention: No exercise or posture (Control)
Number of subjects: 149
Study: 2243887

Group type: EXPERIMENTAL
Intervention: Oral pilocarpine (25 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 354047

Group type: EXPERIMENTAL
Intervention: Oxamniquine (Vansil) at an oral dose of 15 mg/kg twice a day for 2 days (total dose 60 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxamniquine (Vansil)
Number of subjects: 0
Study: 30876430

Group type: EXPERIMENTAL
Intervention: Mechanical dropper (group M)
Number of subjects: 200

Group type: COMPARATOR
Intervention: T-connector (group C)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study: 28150516

Group type: EXPERIMENTAL
Intervention: IDegLira (fixed-ratio combination of insulin degludec and liraglutide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alternative insulin regimens
Number of subjects: 0
Study: 26012938

Group type: EXPERIMENTAL
Intervention: Therapeutic knee and postural stabilization exercises (Group 1, n=22)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Therapeutic knee exercises only (Group 2, n=20)
Number of subjects: 42
Study: 23503652

Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxyvitamin D3 (1,25D)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Transfection of pre-miR-100 and pre-miR-125b with 1,25D
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Transfection of pre-miR-100 and pre-miR-125b
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pre-miR-125b transfection
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Knockdown of miR-125b in normal cells
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 1,25D
Number of subjects: 45
Study: 21562841

Group type: EXPERIMENTAL
Intervention: Mobile-bearing TKA
Number of subjects: 33

Group type: COMPARATOR
Intervention: Fixed-bearing TKA
Number of subjects: 33
Study: 19500615

Group type: EXPERIMENTAL
Intervention: Target preview (specific condition)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Categorical condition (without target preview)
Number of subjects: 0
Study: 16402278

Group type: EXPERIMENTAL
Intervention: Paclitaxel alone (175 mg/m2/IV)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Paclitaxel with Tamoxifen (TAM) (160 mg/m2 PO BID on Days 1-5 followed by paclitaxel 175 mg/m2/IV on Day 5)
Number of subjects: 10
Study: 15306531

Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg (n = 12)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 22
Study: 11673304

Group type: EXPERIMENTAL
Intervention: Stereophotographs using a stereoviewer
Number of subjects: 150

Group type: COMPARATOR
Intervention: Single image from the same stereopair (monoscopic)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Stereoscopic imaging (interobserver)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Monoscopic imaging (interobserver)
Number of subjects: 150
Study: 9408613

Group type: COMPARATOR
Intervention: High-osmolar contrast
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Low-osmolar contrast
Number of subjects: 111
Study: 8353089

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg three times a day for 15 days
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 29923950

Group type: EXPERIMENTAL
Intervention: Costoclavicular approach (Gp-CC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lateral sagittal approach (Gp-LS)
Number of subjects: 40
Study: 27543595

Group type: EXPERIMENTAL
Intervention: Standardized daptomycin dosing protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preimplementation group (control)
Number of subjects: 0
Study: 25231685

Group type: EXPERIMENTAL
Intervention: Comprehensive pharmacologic cancer pain therapy (CPT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no CPT)
Number of subjects: 52
Study: 22321082

Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Mask Airway™ (ILMA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Laryngeal Mask Airway CTrach™ (LMA CTrach)
Number of subjects: 80
Study: 20600025

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) monotherapy
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Fixed-dose emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) combination therapy
Number of subjects: 105

Group type: COMPARATOR
Intervention: TDF monotherapy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Combination therapy (FTC/TDF)
Number of subjects: 105
Study: 18513662

Group type: EXPERIMENTAL
Intervention: Kangaroo Care (skin contact) for 30 minutes before heel stick
Number of subjects: 10

Group type: COMPARATOR
Intervention: Incubator care (inclined, nested and prone)
Number of subjects: 10
Study: 16162447

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 0
Study: 12736834

Group type: EXPERIMENTAL
Intervention: Swimmers
Number of subjects: 20

Group type: COMPARATOR
Intervention: Runners
Number of subjects: 20
Study: 10368942

Group type: EXPERIMENTAL
Intervention: Variable-time schedule
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Different variable-interval schedule
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Extinction condition
Number of subjects: 15

Group type: COMPARATOR
Intervention: Baseline condition (same schedule of reinforcement)
Number of subjects: 15
Study: 8874257

Group type: EXPERIMENTAL
Intervention: i.v. dobutamine (n = 13)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: milrinone (n = 10)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: diuretic responsive (group A; n = 6)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: diuretic resistant (group B; n = 23)
Number of subjects: 29

Group type: COMPARATOR
Intervention: healthy control subjects (n = 25)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 1 week after hospital discharge (group A)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 1 week after hospital discharge (group B)
Number of subjects: 29
Study: 1517949

Group type: EXPERIMENTAL
Intervention: Formula with whey-to-casein ratio 60/40
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formula with whey-to-casein ratio 50/50
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formula with whey-to-casein ratio 35/65
Number of subjects: 0

Group type: COMPARATOR
Intervention: Human milk protein (HMP)‐fortified human milk
Number of subjects: 0
Study: 6385261

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide-mitoxantrone-5-fluorouracil
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cyclophosphamide-doxorubicin-5-fluorouracil
Number of subjects: 44
Study: 31882015

Group type: EXPERIMENTAL
Intervention: Intraoperative VR immersion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 40
Study: 29857856

Group type: EXPERIMENTAL
Intervention: Imaging training for investigators
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: Local investigators' assessment of imaging criteria
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: Local investigators' assessment of DWI-FLAIR mismatch
Number of subjects: 1069
Study: 27507131

Group type: EXPERIMENTAL
Intervention: High-glycemic load diet
Number of subjects: 82
Study: 24169211

Group type: EXPERIMENTAL
Intervention: PCA3 positive men (PCA3 ≥ 35) underwent initial biopsy (IBx) - 12 cores.
Number of subjects: 2366

Group type: COMPARATOR
Intervention: Men randomized to observation (PCA3 < 35)
Number of subjects: 2366

Group type: EXPERIMENTAL
Intervention: PCA3 positive group
Number of subjects: 2366

Group type: COMPARATOR
Intervention: PCA3 negative group
Number of subjects: 2366

Group type: EXPERIMENTAL
Intervention: PCA3 as a second line biomarker
Number of subjects: 2366
Study: 22376194

Group type: EXPERIMENTAL
Intervention: 8-week (5×/week) aerobic cycling training with lower limb weights
Number of subjects: 133

Group type: COMPARATOR
Intervention: Low-intensity overground walking
Number of subjects: 133
Study: 19530976

Group type: EXPERIMENTAL
Intervention: Verteporfin PDT
Number of subjects: 364

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 364
Study: 17977860

Group type: EXPERIMENTAL
Intervention: Group S (warning of a 'sting')
Number of subjects: 101

Group type: COMPARATOR
Intervention: Group NS (no warning of a 'sting')
Number of subjects: 101
Study: 15310639

Group type: COMPARATOR
Intervention: Caudal 0.25% plain bupivacaine 0.5 mL.kg(‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Caudal 0.25% plain bupivacaine 0.5 mL.kg(‐1) with neostigmine 2 microg.kg(‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Caudal 0.25% plain bupivacaine 0.5 mL.kg(‐1) with neostigmine 3 microg.kg(‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Caudal 0.25% plain bupivacaine 0.5 mL.kg(‐1) with neostigmine 4 microg.kg(‐1)
Number of subjects: 80
Study: 11781224

Group type: EXPERIMENTAL
Intervention: High-purity factor VIII/von Willebrand factor concentrate
Number of subjects: 81
Study: 9846530

Group type: EXPERIMENTAL
Intervention: Tacrolimus and prednisone (double-drug therapy)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Tacrolimus, prednisone, and mycophenolate mofetil (triple-drug therapy)
Number of subjects: 200
Study: 7747094

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg once daily for 3 days
Number of subjects: 150

Group type: COMPARATOR
Intervention: Roxithromycin 150 mg bid for 10 days
Number of subjects: 150
Study: 2687356

Group type: EXPERIMENTAL
Intervention: 0.75 mg haloperidol i.v.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6